Has Fernando Membreno, MD received payments from drug or device companies?

Yes. Drug and device makers reported $257,874 in general payments to Fernando Membreno, MD across 314 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fernando Membreno, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fernando Membreno, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fernando Membreno, MD

Transplant Hepatology · McAllen, TXNPI 1942233929

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $208,219 of the $257,874 with a category attached, or 80.7%. 16 manufacturers reported payments, led by Gilead at 58.8% of the total. 2025 is the largest year on record at $115,709, 3.0 times the $38,857 reported in 2019. Among transplant hepatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$257,874in general payments, 2019–2025

Across 314 payments — averaging $821.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$152K
Madrigal Pharmaceuticals$68K
Ipsen Biopharmaceuticals, Inc$37K
Mallinckrodt Hospital Products Inc.$380
Melinta Therapeutics, LLC$264
Exact Sciences$252
plus $890 from 10 others

$477,869in research payments, 2019–2025

Across 28 payments — averaging $17,067 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$413K
Madrigal Pharmaceuticals$34K
Corcept Therapeutics$27K
E.r. Squibb & Sons, L.L.C.$4K

What the payments were for

Consulting fees$7,3603%
Speaking & faculty fees$208,21981%
Travel & lodging$32,94813%
Food & beverage$9,3474%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	180	$151,537
Madrigal Pharmaceuticals	59	$67,708
Ipsen Biopharmaceuticals, Inc	43	$36,842
Mallinckrodt Hospital Products Inc.	8	$380
Melinta Therapeutics, LLC	4	$264
Exact Sciences	3	$252
AstraZeneca	4	$246
Boston Scientific	3	$186
Dova Pharmaceuticals	1	$114
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$100
Boehringer Ingelheim	1	$80
Fujifilm Healthcare Americas Corporation	2	$58
Novo Nordisk	2	$41
AbbVie	1	$28
Medtronic	1	$21
Intercept Pharmaceuticals, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Epclusa$112,112
REZDIFFRA$66,722
IQIRVO$36,282
Livdelzi$30,795
Bylvay$143
TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$138
TERLIVAZ$136
Rezzayo$124
Vabomere$123
Vemlidy$115
DOPTELET$114
RESMETIROM$107
LOKELMA$106

How this compares

$257,874 in reported general payments places this provider in the 90th percentile of 28 transplant hepatology providers in Texas.

See all transplant hepatology providers in Texas →

Medicare billing

Part B allowed, 2024

$11,791

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ursodiol	16	$1,651
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg	12	$321
Spironolactone	25	$205
Furosemide	15	$46
Carvedilol	14	$19

Paid to pharmacies, not to this prescriber.

Other transplant hepatology in McAllen

Abdullah MubarakTyler$362K
Stevan GonzalezFort Worth$282K
David VictorHouston$249K
Prasun JalalHouston$247K
Carmen LandaverdeSan Antonio$189K
Hector NazarioDallas$161K
Ashwini MehtaDallas$100K
Mangesh PagadalaDallas$84K
Madhavi RudrarajuSan Antonio$41K
Kavish PatidarHouston$22K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →